Rapid Deployment Valve for Aortic Stenosis Ups Stroke Risk

Share this content:
Rapid Deployment Valve for Aortic Stenosis Ups Stroke Risk
Rapid Deployment Valve for Aortic Stenosis Ups Stroke Risk

FRIDAY, April 13, 2018 (HealthDay News) -- For patients with aortic valve stenosis, treatment with a rapid deployment valve (RDV) is associated with increased rates of new-onset pacemaker implantation and disabling stroke, compared with conventional biological valves (CBVs), according to a study published in the April 3 issue of the Journal of the American College of Cardiology.

Stephan Ensminger, M.D., from Ruhr-University Bochum in Germany, and colleagues enrolled 22,062 patients who underwent isolated surgical aortic valve replacement using CBV or RDV between 2011 and 2015. Researchers used 1:1 propensity score matching to analyze baseline, procedural, and in-hospital outcome parameters for CBVs and RDVs. A total of 20,937 patients received a CBV, and 1,125 were treated with an RDV.

The researchers found that for patients treated with an RDV versus a CBV, there were significantly reduced times for procedure (150 versus 160 minutes), cardiopulmonary bypass (70 versus 83 minutes), and aortic cross clamp (44 versus 60 minutes; P < 0.001 for all). However, patients treated with an RDV showed significantly elevated rates of pacemaker implantation (8.8 versus 3.7 percent) and disabling stroke (2.2 versus 0.9 percent; both P < 0.001); in-hospital mortality was similar (2.2 versus 1.7 percent; P = 0.22). After propensity score matching, these findings persisted. Comparison of three RDVs showed statistically non-significant differences in pacemaker rates, but significantly different postoperative transvalvular gradients.

"In this large, all-comers database, the incidence of pacemaker implantation and disabling stroke was higher with RDVs, whereas no beneficial effect on in-hospital mortality was seen," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »